Hum. Reprod. Advance Access published online on April 29, 2004
Human Reproduction, doi:10.1093/humrep/deh257
© 2004 by European Society of Human Reproduction and Embryology
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 IVF Unit, Division of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel
* To whom correspondence should be addressed. E-mail: meirow{at}post.tau.ac.il.
BACKGROUND: It has remained controversial whether and in what way suppression of the pituitary-gonadal axis using GnRH analogues can reduce the destructive effects of chemotherapy on ovarian primordial follicles and thus prevent ovarian failure. GnRH antagonists suppress gonadotrophin levels immediately after administration. In this study we determined whether administration of the GnRH antagonist cetrorelix before exposure to increasing doses of cyclophosphamide (Cy) affected the number of surviving primordial follicles (PMF) in the mice ovary. METHODS: Highly inbred young Balb/c mice (114 females) were injected with 0, 50 and 75 mg/kg of Cy. In each treatment group, half of the females were injected daily with cetrorelix starting 9 days before and 7 days post-administration of Cy. In serial sequential ovarian sections the total number of PMF in both ovaries was counted. RESULTS: Ovaries exposed to Cy at doses of 50 and 75 mg/kg had significantly fewer PMF than those in the control group (P < 0.01). In each of the Cy groups used, pretreatment with cetrorelix resulted in significantly higher numbers of PMF: in the 50 mg/kg Cy group only 14% were destroyed (cetrorelix group) versus 53% (P < 0.001), while in the 75 mg/kg Cy group only 35% of PMF were destroyed versus 54% in animals treated only with Cy (P < 0.004). The interaction between the effect of cetrorelix and the different doses of Cy did not reach statistical significance (P = 0.089, two-way ANOVA). CONCLUSIONS: Administration of the GnRH antagonist cetrorelix to mice significantly decreases the extent of ovarian damage induced by the chemotherapeutic agent Cy. The use of different substerilizing doses of Cy suggested that the extent of protection achieved by the antagonist is dose-dependent and decreases with increasing Cy doses. The results of this study may suggest a possible similar beneficial effect in women undergoing chemotherapy, can explain the discrepancy in results of existing clinical studies and indicate possible pathways for ovarian GnRH agonist protection. Further research and clinical studies are needed in order to confirm these results. Key words:
Key words: chemotherapy/GnRH antagonist/mice/premature ovarian failure
Accepted March 18, 2004
Article
The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Maman, K. Prokopis, J. Levron, A. Carmely, J. Dor, and D. Meirow Does controlled ovarian stimulation prior to chemotherapy increase primordial follicle loss and diminish ovarian reserve? An animal study Hum. Reprod., January 1, 2009; 24(1): 206 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L Meistrich and G. Shetty Hormonal suppression for fertility preservation in males and females Reproduction, December 1, 2008; 136(6): 691 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Blumenfeld and M. von Wolff GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy Hum. Reprod. Update, November 1, 2008; 14(6): 543 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Huser, I. Crha, P. Ventruba, R. Hudecek, J. Zakova, L. Smardova, Z. Kral, and J. Jarkovsky Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients Hum. Reprod., April 1, 2008; 23(4): 863 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Partridge Fertility Preservation Considerations in Young Women with Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 36 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Metallinou, B. Asimakopoulos, A. Schroer, and N. Nikolettos Gonadotropin-Releasing Hormone in the Ovary Reproductive Sciences, December 1, 2007; 14(8): 737 - 749. [Abstract] [PDF]
|
|
|
|
 |
|
 O. Oktem and K. Oktay A Novel Ovarian Xenografting Model to Characterize the Impact of Chemotherapy Agents on Human Primordial Follicle Reserve Cancer Res., November 1, 2007; 67(21): 10159 - 10162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.A.A. Silva and H.I. Brunner Review: Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 593 - 599. [Abstract] [PDF]
|
|
|
|
|
|
D. Meirow, J. Dor, B. Kaufman, A. Shrim, J. Rabinovici, E. Schiff, H. Raanani, J. Levron, and E. Fridman Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury Hum. Reprod., June 1, 2007; 22(6): 1626 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sonmezer and K. Oktay Fertility preservation in young women undergoing breast cancer therapy. Oncologist, May 1, 2006; 11(5): 422 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Blumenfeld and A. Eckman Preservation of Fertility and Ovarian Function and Minimization of Chemotherapy-Induced Gonadotoxicity in Young Women by GnRH-a J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 40 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Raptopoulou, P. Sidiropoulos, and D. T Boumpas Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus Lupus, December 1, 2004; 13(12): 887 - 890. [PDF]
|
|